Constantiam Bio

Executive Summary

Constantiam Biosciences is a functional genomics company that combines deep mutational scanning (DMS) with probabilistic machine learning to interpret genetic variants of uncertain significance (VUS). The company's platform aims to accelerate rare disease diagnosis by providing high-throughput functional characterization of variants, thereby reducing diagnostic odysseys. Additionally, Constantiam's technology enables de-risking of drug target discovery by identifying causal variants and optimizing patient stratification for clinical trials, particularly in oncology and immunology. Founded in 2020 and headquartered in Cambridge, MA, the company operates at the intersection of bioinformatics, high-throughput experimentation, and precision medicine. The market for variant interpretation is substantial, driven by the growing adoption of genomic sequencing and the need to resolve VUS, which account for a significant portion of sequencing results. Constantiam's platform has the potential to become a critical tool for diagnostic labs and pharmaceutical companies. While the company is still in a relatively early stage, its focus on rare diseases and precision therapeutics positions it for strategic partnerships and funding milestones. If successful, Constantiam could transform the standard of care for genetic disease diagnosis and drug development.

Upcoming Catalysts (preview)

• 2026Series A Financing Round60% success
• 2026Key Pharma Partnership for Drug Target Discovery40% success
• 2026Publication of Validation Data in Rare Disease Cohort70% success